BioCryst Pharma (BCRX) Posts Narrower than Expected Q1 Loss of 13c/Share; Reaffirms
Tweet Send to a FriendGet Alerts BCRX Hot Sheet
Price: $1.66 --0%
Revenue Growth %: -70.5%
Financial Fact:
Loss from operations: -5.32M
Today's EPS Names:
ANF, DXLG, FL, More
Revenue Growth %: -70.5%
Financial Fact:
Loss from operations: -5.32M
Today's EPS Names:
ANF, DXLG, FL, More
Trade BCRX Now!
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q1 EPS of ($0.13), $0.13 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $12.2 million versus the consensus estimate of $5.9 million.
BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
BioCryst Pharmaceuticals, Inc. reaffirmed FY2012 guidance.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Abercrombie & Fitch Co. (ANF) Misses Q1 EPS by 4c; Guides FY Below Views
- Shoe Carnival, Inc. (SCVL) Tops Q1 EPS by 6c, Guides Q2 In-Line
- Nordson Corp (NDSN) Reports In-Line Q2 EPS, Q3 Guidance Falls Short
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
